4.8 Article

Autocrine VEGF Signaling Synergizes with EGFR in Tumor Cells to Promote Epithelial Cancer Development

Journal

CELL
Volume 140, Issue 2, Pages 268-279

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2009.12.046

Keywords

-

Funding

  1. Boehringer Ingelheim Fonds
  2. EC [QLG1-CT-2001-00869, LSHC-CT-2006-037731]
  3. Austrian Federal Government's GEN-AU [GZ 200.147/1-VI/1a/2006]
  4. Austrian Science Fund [FWF-P18421, FWF-P18782, SFB-23-B13, DK W1212]
  5. Boehringer Ingelheim Austria
  6. Austrian Science Fund (FWF) [W1212] Funding Source: Austrian Science Fund (FWF)

Ask authors/readers for more resources

It is established that tumor cell-derived VEGF acts on endothelial cells to promote angiogenesis and tumor growth. Here, we demonstrate that in K5-SOS-dependent mouse skin tumors, autocrine VEGF is required for tumor cell proliferation in a cell-autonomous and angiogenesis-independent manner. VEGF is upregulated in SOS-expressing tumors, and its deletion in epidermal cells delays tumorigenesis by suppressing angiogenesis and tumor cell proliferation. Epidermis-specific Flt1 deletion also impairs tumorigenesis and proliferation. Surprisingly, complete tumor inhibition occurs in the absence of VEGF in EGFR mutant mice, demonstrating that VEGFR and EGFR synergize in neoplastic cells to promote tumor growth. Mechanistically, K5-SOS upregulates VEGF, Flt1, and Neuropilin-1 in an Erk-dependent manner, thereby activating an autocrine proliferation loop, whereas EGFR prevents tumor cells from apoptosis. Moreover, Flt1 is upregulated in human SCC, and its inhibition in SCC cells impairs proliferation. Thus, in addition to regulating angiogenesis, VEGF has to be considered as a potent growth factor for epidermal tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available